Regular ArticleEuropean Surveillance of Immunoglobulin Safety—Results of Initial Survey of 1243 Patients with Primary Immunodeficiencies in 16 Countries
References (34)
- et al.
High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease
Lancet
(1987) - et al.
Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patients
J. Pediatr.
(1999) - et al.
Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration
Biologicals
(1998) - et al.
Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency
Am. J. Med.
(1988) - et al.
Outbreak of acute hepatitis C following the use of anti-hepatitis C virus-screened intravenous immunoglobulin therapy
Gastroenterology
(1996) - et al.
Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency
Clin. Immunol.
(2001) - et al.
Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C
Clin. Immunol.
(2001) - et al.
Rapid subcutaneous immunoglobulin infusions in children
Lancet
(1993) - et al.
Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency
Clin. Immunol.
(2001) - et al.
In vitro induction of T cell-dependent B cell differentiation in patients with common varied immunodeficiency
Clin. Immunol. Immunopathol.
(1988)
Hypogammaglobulinaemia in the United Kingdom, Summary report of a Medical Research Council working-party
Lancet
Primary hypogammaglobulinaemia: A survey of clinical manifestations and complications
Quart. J. Med.
Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International Union of Immunological Societies
Clin. Exp. Immunol.
Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment
Prep. Biochem. Biotechnol.
A likelihood-based method of identifying contaminated lots of blood product
Int. J. Epidemiol.
Product equivalence study comparing the tolerability, pharmacokinetics, and pharmacodynamics of various human immunoglobulin-G formulations
J. Clin. Pharmacol.
Cited by (0)
- 1
To whom correspondence and reprint requests should be addressed. Fax: 0039-6-4466209. E-mail: [email protected].
- 2
The European Study Group for the Surveillance of Immunoglobulin Safety: D. Richter, Croatia; R. Zachova and J. Litzman, Czech Republic; H. Permin, Denmark; M. Borte and V. Aumann, Germany; E. Papadopulos and F. Kanakoudi-Tsakalidou, Greece; T. Timar, Hungary; C. Feighery, M. Abuzakouk, Ireland; J. Levy, Israel; D. De Mattia, M. Martire, A. Plebani, F. Aiuti, M. Pietrogrande, C. Pietrogrande, P. A. Tovo, V. Monafo, P. Rossi, and C. Pignata, Italy; E. Bernatowska and G. Siwinska, Poland; T. Espanol and M. Vendrell, Spain; J. Bjorkander, K. Elnersson, and V. A. Oxelius, Sweden; E. Gerritsen, The Netherlands; N. Kutukculer, Turkey; F. Ashwoth, H. Chapel, S. J. Deacock, H. C. Gooi, S. L. Johnston, A. Jones, E. Kaminsky, and P. S. Vickers, United Kingdom; S. Pasic, Yugoslavia.